Barba Pere, Burns Linda J, Litzow Mark R, Juckett Mark B, Komanduri Krishna V, Lee Stephanie J, Devlin Sean M, Costa Luciano J, Khan Shakila, King Andrea, Klein Andreas, Krishnan Amrita, Malone Adriana, Mir Muhammad, Moravec Carina, Selby George, Roy Vivek, Cochran Melissa, Stricherz Melisa K, Westmoreland Michael D, Perales Miguel-Angel, Wood William A
Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Hematology Department. Hospital Universitario Vall d'Herbon-Universidad Autonoma de Barcelona.
Biol Blood Marrow Transplant. 2016 Mar;22(3):564-570. doi: 10.1016/j.bbmt.2015.12.008. Epub 2015 Dec 21.
The American Society for Blood and Marrow Transplantation (ASBMT) Clinical Case Forum (CCF) was launched in 2014 as an online secure tool to enhance interaction and communication among hematopoietic cell transplantation (HCT) professionals worldwide through the discussion of challenging clinical care issues. After 14 months, we reviewed clinical and demographical data of cases posted in the CCF from January 29, 2014 to March 18, 2015. A total of 137 cases were posted during the study period. Ninety-two cases (67%) were allogeneic HCT, 29 (21%) were autologous HCT, and in 16 (12%), the type of transplantation (autologous versus allogeneic) was still under consideration. The diseases most frequently discussed included non-Hodgkin lymphoma (NHL; n = 30, 22%), acute myeloid leukemia (n = 23, 17%), and multiple myeloma (MM; n = 20, 15%). When compared with the US transplantation activity reported by the US Department of Health and Human Services, NHL and acute lymphoblastic leukemia cases were over-represented in the CCF, whereas MM was under-represented (P < .001). A total of 259 topics were addressed in the CCF with a median of 2 topics/case (range, 1 to 6). Particularly common topics included whether transplantation was indicated (n = 57, 41%), conditioning regimen choice (n = 44, 32%), and post-HCT complications after day 100 (n = 43, 31%). The ASBMT CCF is a successful tool for collaborative discussion of complex cases in the HCT community worldwide and may allow identification of areas of controversy or unmet need from clinical, educational and research perspectives.
美国血液与骨髓移植学会(ASBMT)临床病例论坛(CCF)于2014年启动,作为一个在线安全工具,通过讨论具有挑战性的临床护理问题,加强全球造血细胞移植(HCT)专业人员之间的互动和交流。14个月后,我们回顾了2014年1月29日至2015年3月18日在CCF上发布的病例的临床和人口统计学数据。研究期间共发布了137例病例。92例(67%)为异基因HCT,29例(21%)为自体HCT,16例(12%)的移植类型(自体与异基因)仍在考虑中。讨论最频繁的疾病包括非霍奇金淋巴瘤(NHL;n = 30,22%)、急性髓系白血病(n = 23,17%)和多发性骨髓瘤(MM;n = 20,15%)。与美国卫生与公众服务部报告的美国移植活动相比,CCF中NHL和急性淋巴细胞白血病病例的比例过高,而MM的比例过低(P <.001)。CCF共涉及259个主题,每个病例的主题中位数为2个(范围为1至6个)。特别常见的主题包括是否适合进行移植(n = 57,41%)、预处理方案的选择(n = 44,32%)以及移植后100天后的并发症(n = 43,31%)。ASBMT CCF是全球HCT社区协作讨论复杂病例的成功工具,可能有助于从临床、教育和研究角度识别有争议或未满足需求的领域。